Science misinformation alarms Francis Collins as he leaves top NIH job
By Nidhi Subbaraman,
Nature
| 12. 03. 2021
The genome project leader reflects on his 12 years at the helm of a juggernaut biomedical agency, and what lies ahead.
This month, Francis Collins will step down as director of the US National Institutes of Health (NIH) after more than 12 years leading the agency, the world’s biggest public funder of biomedical research. A former head of the Human Genome Project, he championed similar bold, big-budget science efforts, such as the All of Us Project, which aims to study health data from one million people. He led the NIH under three US presidents, steered it through a roiling pandemic, and faced myriad clashes over politics and biomedical science. Collins will stay on at the NIH to continue research in his lab. He spoke to Nature about some highlights of his time at the helm, and issues facing the agency in the future.
Which achievement will you cherish most?
It’s really hard to pick one. Maybe it’s where it was possible to bring together scientists of multiple disciplines and organize a truly bold, audacious project that would simply not have happened if one just counted on it coming together passively. I’m thinking of the BRAIN Initiative. I’m thinking of what...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...